Bausch + Lomb (BLCO)
(Delayed Data from NYSE)
$16.43 USD
+0.43 (2.69%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $16.46 +0.03 (0.18%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth D Momentum D VGM
Brokerage Reports
0 items in cart
Bausch + Lomb Corporation [BLCO]
Reports for Purchase
Showing records 1 - 17 ( 17 total )
Company: Bausch + Lomb Corporation
Industry: Medical Services
Company: Bausch + Lomb Corporation
Industry: Medical Services
2023 Financial Results Reported; Reiterate Buy; Adjusting PT to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Bausch + Lomb Corporation
Industry: Medical Services
Optimized Entry and Exit Levels for BLCO 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Bausch + Lomb Corporation
Industry: Medical Services
Company: Bausch + Lomb Corporation
Industry: Medical Services
XIIDRA Acquisition Completed; Reiterate Buy; Modulating PT to $21
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Bausch + Lomb Corporation
Industry: Medical Services
Company: Bausch + Lomb Corporation
Industry: Medical Services
XIIDRA To Be Acquired By End-2023 For $1.75 Billion; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Bausch + Lomb Corporation
Industry: Medical Services
MIEBO (NOV03) Approved For Signs and Symptoms of Dry Eye Disease; Reiterate Buy; Raising PT to $22
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Bausch + Lomb Corporation
Industry: Medical Services
1Q23 Financial Results Reported; Reiterate Buy; Lowering PT to $19
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Bausch + Lomb Corporation
Industry: Medical Services
Second Pivotal Trial of NOV03 Published; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Bausch + Lomb Corporation
Industry: Medical Services
Full-Year 2022 Financial Results Reported; Reiterate Buy; Modulating PT to $21
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Bausch + Lomb Corporation
Industry: Medical Services
HCW 2023 Top Picks: Seize the Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Bausch + Lomb Corporation
Industry: Medical Services
Novel Photodynamic Laser for AMD Receives U.S. Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Bausch + Lomb Corporation
Industry: Medical Services
NOV03 Phase 3 Dry Eye Data Published; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Bausch + Lomb Corporation
Industry: Medical Services
3Q22 Financial Results Reported; Reiterate Buy; Modulating PT to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Bausch + Lomb Corporation
Industry: Medical Services
EMA Adopts Positive Opinion For Ranibizumab Biosimilar Candidate; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Bausch + Lomb Corporation
Industry: Medical Services
An Integrated Global Eye Care Conglomerate; Initiating at Buy and $21 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
|